4.6 Article

Disparities in Reported Testing for 1p/19q Codeletion in Oligodendroglioma and Oligoastrocytoma Patients: An Analysis of the National Cancer Database

Related references

Note: Only part of the references are listed.
Article Oncology

CODEL: phase III study of RT, RT plus TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design

Kurt A. Jaeckle et al.

Summary: The study demonstrated that patients treated with temozolomide alone had significantly shorter progression-free survival (PFS) compared to those receiving radiotherapy. Patients not receiving radiotherapy also had shorter PFS, but there was no significant difference in overall survival. There were no significant differences between groups in terms of adverse events and neurocognitive decline.

NEURO-ONCOLOGY (2021)

Article Clinical Neurology

Community economic factors influence outcomes for patients with primary malignant glioma

Aaron Bower et al.

NEURO-ONCOLOGY PRACTICE (2020)

Article Oncology

Barriers to accrual and enrollment in brain tumor trials

Eudocia Q. Lee et al.

NEURO-ONCOLOGY (2019)

Article Oncology

Racial Disparities in the Molecular Landscape of Cancer

Elisabeth I. Heath et al.

ANTICANCER RESEARCH (2018)

Article Clinical Neurology

Disparities in health care determine prognosis in newly diagnosed glioblastoma

Ankush Chandra et al.

NEUROSURGICAL FOCUS (2018)

Article Oncology

Updates in prognostic markers for gliomas

Elisa Aquilanti et al.

NEURO-ONCOLOGY (2018)

Editorial Material Clinical Neurology

Racial disparities in anaplastic oligodendroglioma: An analysis on 1643 patients

Jacob Y. Shin et al.

JOURNAL OF CLINICAL NEUROSCIENCE (2017)

Review Oncology

Using the National Cancer Database for Outcomes Research

Daniel J. Boffa et al.

JAMA ONCOLOGY (2017)

Article Medicine, General & Internal

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors

Jeanette E. Eckel-Passow et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Article Oncology

Loss of heterozygosity 1p/19q and survival in glioma: a meta-analysis

Jiaxin Zhao et al.

NEURO-ONCOLOGY (2014)

Article Oncology

Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402

Gregory Cairncross et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

Review Oncology

Central Nervous System Cancers Clinical Practice Guidelines in Oncology

Louis Burt Nabors et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)

Article Surgery

Disparities in Access to Neuro-oncologic Care in the United States

Debraj Mukherjee et al.

ARCHIVES OF SURGERY (2010)

Article Clinical Neurology

All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2

M. Labussiere et al.

NEUROLOGY (2010)

Review Oncology

Racial, ethnic and socioeconomic disparities in the treatment of brain tumors

William T. Curry et al.

JOURNAL OF NEURO-ONCOLOGY (2009)

Article Oncology

The National Cancer Data Base: A powerful initiative to improve cancer care in the United States

Karl Y. Bilimoria et al.

ANNALS OF SURGICAL ONCOLOGY (2008)